HepB-CpG 在接种后确诊妊娠女性中的安全性与免疫原性:一项回顾性病历审查
本研究回顾性审查了 HepB-CpG 关键注册临床试验中接种后确诊妊娠的参与者,比较 HepB-CpG 组与 HepB-alum 组的血清保护率和抗-HBs 几何平均浓度,并通过病历审查确认妊娠结局。结果显示 HepB-CpG 组血清保护率为 97.2%,HepB-alum 组为 66.7%,妊娠结局两组相似。作者认为这些有限数据提示 HepB-CpG 在接种后妊娠女性中具有免疫原性,但需更大规模的前瞻性研究进一步验证。
要点
- HepB-CpG 组接种后妊娠者血清保护率为 97.2%(95% CI 85.5-99.9),HepB-alum 组为 66.7%(95% CI 41.0-86.7)
- HepB-CpG 组 36 例有妊娠结局记录者中,21/36(58%)为健康足月分娩,3/36(8%)自然流产,1/36(3%)先天畸形,2/36(6%)早产
- 作者认为这些有限数据提示 HepB-CpG 在接种后妊娠女性中具有免疫原性,妊娠结局与 HepB-alum 组相似,但需更大规模前瞻性研究进一步验证
核心结论
- 这些有限数据提示 HepB-CpG 在接种后妊娠女性中具有免疫原性,妊娠结局与接种 HepB-alum 后妊娠的女性相似。
- 这些结果需通过更大规模、在妊娠期接种 HBV 疫苗的前瞻性研究进一步验证。
研究设计与样本
- 回顾性病历审查,纳入 HepB-CpG 关键注册前临床试验中研究随访期间确诊妊娠的所有参与者。
- HepB-CpG 组 40 例确诊妊娠,HepB-alum 组 19 例确诊妊娠。
- 通过 FDA 批准的抗-HBsAg 抗体检测在预设时间点(随访至 28 周)比较两组血清保护率(抗-HBs ≥ 10 mIU/mL)和抗-HBs 几何平均浓度。
- 妊娠结局通过提取研究参与者病历进行审查确认。
主要发现
- 在有血清保护率记录者中,HepB-CpG 组 97.2%(95% CI 85.5-99.9)达到血清保护,HepB-alum 组 66.7%(95% CI 41.0-86.7)达到血清保护。
- HepB-CpG 组 36 例报告妊娠结局者中,21/36(58%)为健康足月分娩,3/36(8%)自然流产,1/36(3%)先天畸形,2/36(6%)早产。
- HepB-alum 组 17 例报告妊娠结局者中,10/17(59%)为健康足月分娩,2/17(12%)自然流产,1/17(6%)先天畸形。
关键数值与推荐
- 血清保护定义为抗-HBs ≥ 10 mIU/mL。
- HepB-CpG 组血清保护率 97.2%(95% CI 85.5-99.9),HepB-alum 组 66.7%(95% CI 41.0-86.7)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文称这些数据有限(limited data)。
- 原文指出这些结果需通过更大规模、在妊娠期接种 HBV 疫苗的前瞻性研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are currently no published data on the use of HepB-CpG (HEPLISAV-B®) during pregnancy or in women with documented pregnancies in the post-vaccination period. We aimed to evaluate data from the clinical development program of HepB-CpG in women who became pregnant during study participation and follow up. METHODS: We identified all study participants in the HepB-CpG pivotal pre-licensure clinical trials that had documented pregnancies during study follow up. We measured immunogenicity among study participants in the HepB-CpG (Heplisav-B®) arm compared to the HepB-alum (Engerix-B®) arm of the studies by comparing seroprotection rates (SPRs; anti-HBs ≥ 10 mIU/mL) and geometric mean concentrations (GMCs) of anti-HBs, obtained with FDA approved anti-HBsAg antibody assays at prespecified time points up to 28 weeks of follow up. Pregnancy outcomes were ascertained by chart review of extracted medical records of study participants. RESULTS: We identified 40 documented pregnancies in the HepB-CpG arm and 19 documented pregnancies in the HepB-alum arm. Among subjects with documentation of seroprotection rates, 97.2% (95% CI 85.5-99.9) were seroprotected in the HepB-CpG arm and 66.7% (95% CI 41.0-86.7) were seroprotected in the HepB-alum arm. In the HepB-CpG arm, thirty-six study participants from the pivotal trials had reported pregnancy outcomes, the majority, 21/36 (58%) had a healthy term delivery, with 3/36 (8%) with spontaneous abortions, 1/36 (3%) congenital anomaly, and 2/36 (6%) had preterm birth. In the HepB-alum arm, 10/17 (59%) had healthy term deliveries, with 2/17 (12%) had spontaneous abortions and 1/17 (6%) had congenital anomaly. CONCLUSIONS: These limited data suggest that HepB-CpG is immunogenic in women who become pregnant after vaccination, and pregnancy outcomes appear to be similar to women who received HepB-alum prior to pregnancy. These results need to be further verified with larger prospective studies with HBV vaccine administration during pregnancy.
引用
- Kushner T, Huang V, Janssen R, et al. Safety and immunogenicity of HepB-CpG in women with documented pregnancies post-vaccination: A retrospective chart review. Vaccine. 2022. PMID: 35430105. doi:10.1016/j.vaccine.2022.04.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。